Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study.
CT scan
Kidney transplantation
Mortality risk factors
Myosteatosis
Prognosis
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
27
09
2021
received:
20
07
2021
accepted:
30
09
2021
pubmed:
6
11
2021
medline:
24
3
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
Patients with end-stage renal disease may display both a loss of skeletal muscle mass and an increase in muscle fat deposits. We aimed to analyse the impact of low skeletal muscle mass index (SMI, surrogate marker of sarcopenia) and low muscle density (MD, surrogate marker of myosteatosis) on patient survival after kidney transplantation (KT). In a retrospective cohort of 200 kidney transplant recipients (KTr), we measured on an unenhanced cross-sectional computed tomography scan taken at the level of the third lumbar vertebra within the previous year or at the time of KT, both SMI (muscle cross-sectional area normalized for height Among the 200 patients of the cohort, 123 were male (62%), and mean age was 54.8 ± 13.8 years. A total of 181 KTr required renal replacement therapy before KT (91%), and 36 KTr (18%) received repeat kidney transplant after previous failed KT. Mean MD was 30.6 ± 9 HU in men and 29.7 ± 8.3 HU in women, whereas SMI was 49.7 ± 8.6 cm Myosteatosis, which was more prevalent than low skeletal muscle mass, might be an important prognostic marker in patients undergoing KT.
Sections du résumé
BACKGROUND
Patients with end-stage renal disease may display both a loss of skeletal muscle mass and an increase in muscle fat deposits. We aimed to analyse the impact of low skeletal muscle mass index (SMI, surrogate marker of sarcopenia) and low muscle density (MD, surrogate marker of myosteatosis) on patient survival after kidney transplantation (KT).
METHODS
In a retrospective cohort of 200 kidney transplant recipients (KTr), we measured on an unenhanced cross-sectional computed tomography scan taken at the level of the third lumbar vertebra within the previous year or at the time of KT, both SMI (muscle cross-sectional area normalized for height
RESULTS
Among the 200 patients of the cohort, 123 were male (62%), and mean age was 54.8 ± 13.8 years. A total of 181 KTr required renal replacement therapy before KT (91%), and 36 KTr (18%) received repeat kidney transplant after previous failed KT. Mean MD was 30.6 ± 9 HU in men and 29.7 ± 8.3 HU in women, whereas SMI was 49.7 ± 8.6 cm
CONCLUSIONS
Myosteatosis, which was more prevalent than low skeletal muscle mass, might be an important prognostic marker in patients undergoing KT.
Identifiants
pubmed: 34738343
doi: 10.1002/jcsm.12853
pmc: PMC8818595
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
386-396Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Obesity (Silver Spring). 2013 Oct;21(10):2118-25
pubmed: 23408772
Nephrology (Carlton). 2010 Jun;15(4):454-63
pubmed: 20609098
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):111-122
pubmed: 30460764
N Engl J Med. 1999 Dec 2;341(23):1725-30
pubmed: 10580071
Nephrol Dial Transplant. 2019 Aug 1;34(8):1344-1353
pubmed: 29939315
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Front Physiol. 2020 Aug 07;11:963
pubmed: 32903666
Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1720-8
pubmed: 25074839
Nephrol Dial Transplant. 2015 Oct;30(10):1718-25
pubmed: 25999376
Clin Nutr. 2017 Dec;36(6):1654-1660
pubmed: 27816311
Crit Care. 2016 Dec 1;20(1):386
pubmed: 27903267
Crit Rev Oncol Hematol. 2020 Jan;145:102839
pubmed: 31877534
Hepatol Res. 2016 Sep;46(10):951-63
pubmed: 27481650
J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):358-367
pubmed: 33525056
Am J Transplant. 2020 Feb;20(2):493-503
pubmed: 31448486
J Ren Nutr. 2021 May;31(3):286-295
pubmed: 33139208
BMC Nephrol. 2016 Oct 22;17(1):158
pubmed: 27770799
Am J Kidney Dis. 2014 Mar;63(3):491-9
pubmed: 24210591
Eur Radiol. 2018 Jun;28(6):2455-2463
pubmed: 29318425
Electrolyte Blood Press. 2007 Dec;5(2):126-30
pubmed: 24459511
Obesity (Silver Spring). 2016 Feb;24(2):476-82
pubmed: 26694517
Transplantation. 2016 Mar;100(3):630-9
pubmed: 26714121
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):915-925
pubmed: 28627027
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Metabolism. 2020 Oct;111:154321
pubmed: 32712219
J Gerontol A Biol Sci Med Sci. 2015 Sep;70(9):1133-40
pubmed: 25838547
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):386-396
pubmed: 34738343
Clin J Am Soc Nephrol. 2011 Jun;6(6):1463-73
pubmed: 21415312
Kidney Int. 1998 May;53(5):1343-7
pubmed: 9573550
J Am Soc Nephrol. 2003 Sep;14(9):2366-72
pubmed: 12937315
Am J Transplant. 2006 Feb;6(2):262-74
pubmed: 16426310
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
J Ren Nutr. 2019 Nov;29(6):511-520
pubmed: 30686748
Transplantation. 2002 Nov 15;74(9):1281-6
pubmed: 12451266
Diagn Interv Imaging. 2020 Dec;101(12):789-794
pubmed: 32451309
Eur J Clin Nutr. 2018 Feb;72(2):288-296
pubmed: 29242526
Am J Transplant. 2009 Mar;9(3):527-35
pubmed: 19191769
Ann N Y Acad Sci. 2000 May;904:18-24
pubmed: 10865705
Neurorehabil Neural Repair. 2011 Nov-Dec;25(9):865-72
pubmed: 21734070
Front Physiol. 2020 Feb 25;11:130
pubmed: 32161551
Kidney Int. 2016 Jul;90(1):53-66
pubmed: 27157695
J Gerontol A Biol Sci Med Sci. 2019 Sep 15;74(10):1671-1678
pubmed: 30726878